<DOC>
	<DOC>NCT01164085</DOC>
	<brief_summary>Intraocular delivery of ketorolac will be an effective means to treat inflammation and macular edema and prevent structural complications and vision loss in patients with uveitis who are unable to tolerate corticosteroids due to their side effects.</brief_summary>
	<brief_title>Intravitreal Ketorolac for Chronic Uveitis: A Investigational Safety Study</brief_title>
	<detailed_description>A Phase I safety study of intravitreal ketorolac in patients with chronic inflammation and complications due to inflammation who have either failed medical therapy or who cannot tolerate corticosteroids due to side effects. Specific Aims 1. Test the safety of intraocular injection of 4mg of ketorolac in patients who have intractable uveitis or complications of uveitis such as chronic macular edema who are unable to tolerate corticosteroids due to their side effects. 2. Test the efficacy of intraocular 4m ketorolac of treating inflammation or structural complications of inflammation in patients with uveitis who are unable to tolerate corticosteroids due to their side effects.</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Ketorolac</mesh_term>
	<mesh_term>Ketorolac Tromethamine</mesh_term>
	<criteria>Adult volunteers Chronic intractable uveitis or chronic complications of uveitis (macular edema)despite maximal medical treatment Unable to tolerate corticosteroids due to side effects 18 years or younger Have active ocular infection Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Inflammation</keyword>
	<keyword>Macular Edema</keyword>
</DOC>